Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevance Health, Inc. (NYSE: ELV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elevance Health operates in the direct health and medical insurance carriers industry and uses its SEC reports to present information on financial performance, capital structure, governance, and material events affecting its health benefits and Carelon segments.
Among the most important documents for ELV are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically include detailed discussions of segment results for Health Benefits and Carelon, membership metrics across commercial, Medicare, Medicaid, and Federal Employee Program lines, risk factors, and management’s analysis of trends in benefit expense ratios, operating expenses, and cash flows. They also describe Elevance Health’s role as a licensee of Blue Cross Blue Shield plans in multiple states and its activities in pharmacy and healthcare services through Carelon.
Elevance Health also files current reports on Form 8-K to disclose specific material events. Recent 8-Ks have covered quarterly earnings releases, reaffirmation of earnings guidance and benefit expense ratio expectations, the election of independent directors to the board and their committee assignments, and a multi-tranche notes offering with maturities extending to 2055. These filings provide insight into governance practices, capital markets activity, and management’s public communications with investors.
Investors interested in executive and board matters can review proxy-related filings and 8-K disclosures regarding director appointments and compensation programs for non-employee directors. Those analyzing Elevance Health’s capital structure can examine registration statements and debt-related exhibits referenced in 8-K filings, which describe terms of senior notes, redemption provisions, and events of default.
On Stock Titan, ELV filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and risk discussions, and help users quickly locate information on topics like Medicare and Medicaid program exposure, pharmacy and services operations under Carelon, and guidance-related forward-looking statements. Users can also review Form 4 insider transaction reports when available to monitor trading activity by Elevance Health directors and officers.
By using this filings page, investors and researchers can navigate Elevance Health’s regulatory history more efficiently, compare disclosures across reporting periods, and better understand how the company presents its health benefits and services business to regulators and the market.
Elevance Health announced management changes and reaffirmed its 2026 financial outlook. Executive Vice President and Carelon President Peter D. Haytaian will leave his Carelon role effective May 4, 2026 to focus on family, and will serve as Special Advisor through December 31, 2026 to support a smooth transition.
Chief Financial Officer Mark Kaye will add oversight of Carelon, the company’s healthcare services operations, while Felicia Norwood will lead a consolidated Health Benefits organization under a single accountable structure. Elevance Health reaffirmed full-year 2026 shareholders’ earnings guidance of at least $22.30 per diluted share, including about $3.20 of net unfavorable items, and at least $25.50 per diluted share on an adjusted basis. The company also reaffirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.
Elevance Health is one of the largest U.S. health insurers, serving about 45.2 million medical members as of December 31, 2025. It operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
The company offers commercial, Medicare, Medicaid, federal employee and specialty plans, and earns revenue from risk-based premiums, self‑funded administrative fees, and pharmacy and health service fees. About 32% of consolidated revenue in 2025 came from U.S. government agencies. Elevance leverages Blue Cross and Blue Shield licenses in multiple states, value‑based provider contracts, and digital tools such as its Sydney Health platform to manage costs and quality.
CarelonRx provides pharmacy benefit management and infusion services, while Carelon Services integrates physical, behavioral, pharmacy and social‑care capabilities. The 10‑K highlights extensive regulation under the ACA, the IRA, Medicaid redeterminations, transparency and privacy rules, and notes that results depend heavily on medical cost trends, membership mix and CMS Star Ratings. The company reports a global workforce of roughly 97,100 employees and emphasizes culture, inclusion and fair pay.
Elevance Health, Inc. director Amy W. Schulman reported an acquisition of 218 shares of Company common stock on February 2, 2026. The Form 4 shows these as an "A" transaction at a price of $0 per share, held as direct ownership after the transaction.
The 218 shares reflect phantom stock units accrued under Elevance Health’s Board of Directors Compensation Program. According to the terms, these phantom stock units will be settled in Company common stock on the earlier of five years after the preceding annual shareholder meeting or when Schulman ceases to serve on the board, unless she has elected a later deferral date.
Elevance Health EVP & Chief HR Officer Craig Ryan reported a routine tax-related share withholding. On February 2, 2026, 279 shares of Elevance Health common stock were withheld at $341.83 per share to cover tax liability from vesting restricted stock. After this transaction, he directly beneficially owned 4,032 common shares.
Elevance Health, Inc. filed a current report stating that it issued a press release with its fourth quarter and full year 2025 financial results. The press release is furnished as Exhibit 99.1 and is not treated as filed for liability purposes under federal securities laws.
The company also includes an extensive caution about forward-looking statements, highlighting risks such as healthcare cost trends, regulatory changes, cyber and data security issues, Medicare and Medicaid program complexities, competitive pressures, indebtedness, and other operational and financial uncertainties.
Elevance Health, Inc. director Amy W. Schulman filed an initial Form 3 ownership report as a board member of the company. The filing states that no securities of Elevance Health are beneficially owned, and both the non-derivative and derivative securities tables are empty. The document also includes a power of attorney authorizing an attorney-in-fact to sign on her behalf.
Elevance Health, Inc. reported that its Board of Directors elected Amy W. Schulman as an independent director on December 10, 2025. Her service will begin on January 12, 2026 and her term will run until the company’s 2028 annual meeting of shareholders. The Board also appointed her to the Audit Committee and the Finance Committee.
The Board determined that Ms. Schulman is an independent director under NYSE listing standards and the company’s own independence guidelines, and that she qualifies as an “audit committee financial expert” under SEC regulations. She will be compensated under Elevance Health’s standard non-employee director compensation program, and the company issued a press release about her election, which is included as an exhibit.
Elevance Health, Inc. (ELV)3,341 shares of common stock, held directly. A portion of this amount represents restricted share units that vest on varying dates between February 1, 2026 and March 3, 2028. This update is administrative in nature and aligns the reported ownership with the accurate share count.
Elevance Health (ELV) reaffirmed its full‑year 2025 guidance. Management continues to expect shareholders’ earnings of approximately $24.70 per diluted share, which includes about $5.30 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders’ earnings are still expected to be approximately $30.00 per diluted share.
The company also reaffirmed its full‑year 2025 benefit expense ratio guidance of approximately 90.0%. These expectations reflect current views on market conditions, operations, policy, and cost trends, and actual results could differ if assumptions change.
Elevance Health (ELV) reported stronger Q3 2025 results. Total revenues were $50.711 billion versus $45.106 billion a year ago, driven by premiums of $41.791 billion (up from $36.809 billion), product revenue of $6.159 billion, and service fees of $2.137 billion. Shareholders’ net income rose to $1.189 billion from $1.016 billion, and diluted EPS increased to $5.32 from $4.36.
For the first nine months, total revenues reached $149.378 billion versus $131.569 billion, while shareholders’ net income was $5.115 billion versus $5.562 billion. Operating cash flow was $4.206 billion versus $5.102 billion.
On the balance sheet, cash and cash equivalents were $8.713 billion, total assets $122.749 billion, and total shareholders’ equity improved to $43.953 billion with accumulated other comprehensive loss narrowing to $(543) million from $(1,147) million. Long-term debt rose to $31.173 billion. The company repurchased $2.134 billion of common stock year-to-date and paid $1.152 billion in dividends. Shares outstanding were 222,238,763 as of October 14, 2025.
Recent acquisitions of Centers and CareBridge were integrated; purchase accounting remains open, with associated goodwill and intangibles recorded.